🟠 Moderate Evidence
Infants born before 32 weeks of gestation who received donated breast milk had a 38% lower rate of necrotizing enterocolitis (NEC)—a life-threatening inflammatory bowel disease—according to research published in the Journal of Paediatrics and Child Health. This marks the first Australian study to systematically examine both benefits and safety risks of human milk donation in very preterm infants.
Key takeaways
- Necrotizing enterocolitis rates fell by 38% in very premature babies receiving donated breast milk
- The study represents the first comprehensive Australian evidence on donated milk safety and efficacy in infants under 32 weeks gestation
- Findings support expanded access to human milk banks as a preventive strategy for preterm infant complications
Study at a Glance
| Source | Journal of Paediatrics and Child Health |
| Study type | Observational cohort analysis |
| Population | Very preterm infants ( |
| Intervention | Donated breast milk from Australian Red Cross Lifeblood |
| Primary outcome | Incidence of necrotizing enterocolitis |
| Country | Australia |
Protective effect of donated breast milk on NEC risk
Relative risk reduction in very preterm infants (
Source: Journal of Paediatrics and Child Health, 2026 | Australian Red Cross Lifeblood | Georgian Medical Journal News
A preventable complication becomes rarer with donated milk
Necrotizing enterocolitis remains one of the most serious complications in neonatal intensive care units, carrying mortality rates of 15–30% in affected infants. The condition, characterized by inflammation and tissue death in the infant bowel, disproportionately affects the most vulnerable patients—those born at extremely low gestational ages. The use of donated human milk, screened and processed by Australian Red Cross Lifeblood, has emerged as a practical intervention to reduce this risk.
The research tracked outcomes in very preterm infants receiving milk from the Lifeblood milk bank program and compared them to historical controls. The 38% reduction in NEC incidence published in the Journal of Paediatrics and Child Health aligns with growing international evidence supporting donor milk as a evidence-based preventive strategy. This finding is particularly significant because it comes from real-world Australian clinical practice rather than controlled trial conditions.
The 38% reduction in necrotizing enterocolitis rates demonstrates that systematically screened, processed donor breast milk can substantially reduce life-threatening complications in the most vulnerable preterm infants.
— Australian Red Cross Lifeblood study team, Journal of Paediatrics and Child Health (2026)
Why this matters for neonatal care standards
The protective effect of donated breast milk operates through multiple biological mechanisms documented in neonatal literature. Human milk contains immunoglobulins, prebiotics, and probiotic-promoting factors that strengthen intestinal barrier function and reduce pathogenic bacterial colonisation. For infants unable to receive their mother’s own milk—whether due to maternal illness, separation, or insufficient production—donor milk represents the closest available alternative.
The Australian findings carry particular weight because they represent the first systematic local evidence on safety and efficacy. Previous international data, including studies referenced in systematic reviews of human milk banking programmes, have demonstrated similar protective patterns, but country-specific data strengthen clinical adoption. This may support policy expansion of milk bank access across Australian neonatal networks and potentially inform similar programmes in other health systems.
Implementation and equity considerations
Scaling donor milk programmes requires investment in screening infrastructure, processing facilities, and cold-chain logistics. The Australian Red Cross Lifeblood programme operates under strict microbiological and serological standards to ensure safety. However, access remains unevenly distributed across regions, raising equity questions about which infants benefit from this protective intervention.
This research suggests that expansion of milk banking infrastructure merits investment as a public health priority for preventing serious neonatal complications. Whether through increased donor recruitment, improved reimbursement models, or integration into standard preterm care protocols, the evidence base now supports aggressive expansion of these programmes. The 38% reduction in a life-threatening condition translates directly to reduced neonatal mortality, shorter intensive care stays, and lower associated healthcare costs.
What this means
What remains to be studied
While the protective effect is clear, future research should examine optimal timing and volume of donor milk introduction, cost-effectiveness compared to formula supplementation, and long-term neurodevelopmental outcomes in infants receiving donor milk. Prospective randomised controlled trials would provide the highest level of evidence, though the ethical imperative to provide donor milk once efficacy is established may make such trials challenging to conduct.
Frequently asked questions
Is donated breast milk safe for premature infants?
Yes. Donor milk screened and processed by accredited milk banks like Australian Red Cross Lifeblood undergoes rigorous testing for infectious diseases and microbial contamination before use. Safety protocols follow international standards established by the International Association of Human Milk Banking. However, raw, unscreened donor milk carries infection risks and should not be used.
Why is donor milk protective against necrotizing enterocolitis?
Human milk contains antibodies (immunoglobulins), prebiotics, and bioactive proteins that strengthen the intestinal lining and promote beneficial bacteria growth. These factors reduce intestinal inflammation and pathogenic bacterial colonisation—the key mechanisms underlying NEC development. Formula, while nutritionally adequate, lacks these immunological components.
How widely available is donor milk in neonatal care?
Availability varies significantly by country and region. Australia now has established milk banking through organisations like Australian Red Cross Lifeblood, but access remains limited in many parts of the world. International recommendations from the World Health Organization support expansion of milk banking as part of universal health coverage for neonatal care.
As evidence supporting donor milk continues to accumulate, the challenge now shifts from proving efficacy to ensuring equitable access. The Australian data provides policymakers with concrete evidence that investment in human milk banking yields measurable reductions in serious neonatal complications. Read more about clinical updates in neonatal care and global health initiatives in improving outcomes for vulnerable populations.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
